rs10250448 - BBS9
Magnitude 2.2 · 1 study on file
Reported associations
-
Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas - Unknown journal (n.d.) · Unknown authors · PubMed 34607834
ABSTRACT: OBJECTIVE Sulfonylureas, the first available drugs for the management of type 2 diabetes, remain widely prescribed today. However, there exists significant variability in glycemic response to treatment. We aimed to establish heritability of sulfonylurea response and identify genetic variants and interacting treatments associated with HbA1c reduction. RESEARCH DESIGN AND METHODS As an initiative of the Metformin Genetics Plus Consortium (MetGen Plus) and the DIabetes REsearCh on patient straTification (DIRECT) consortium, 5,485 White Europeans with type 2 diabetes treated with sulfonylureas were recruited from six referral centers in Europe and North America. We first estimated heritability using the generalized restricted maximum likelihood approach and then undertook genome-wide
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Discuss with your doctor
-
sulfonylurea dosing based on BBS9 genotype Moderate
G allele of rs10250448 (BBS9) is associated with improved HbA1c response to sulfonylurea therapy in type 2 diabetes
If you have type 2 diabetes, discuss this genotype with your prescriber to optimize sulfonylurea selection and dosing